Business Wire

Boehringer Ingelheim: New sub-analyses to be presented at ESC Congress 2018 further support positive safety profile of Pradaxa® (dabigatran etexilate)

Del

Boehringer Ingelheim today announced that it will present nine sub-analyses from the RE-DUAL PCITM trial and GLORIATM-AF Registry Program at the upcoming ESC Congress 2018, organised by the European Society of Cardiology, taking place in Munich, Germany on the 25-29 August 2018. The primary data from these studies have contributed to a positive label update for dabigatran etexilate (Pradaxa®) in the European Union (EU).

The primary RE-DUAL PCITM trial investigated anticoagulation in patients with non-valvular atrial fibrillation (AF) following percutaneous coronary intervention (PCI) and stent placement. Data showed significantly lower rates of major or clinically relevant non-major bleeding events for dual therapy with dabigatran etexilate when compared to triple therapy with warfarin without compromise on efficacy.1,2

GLORIATM-AF is a large, prospective, observational study program run in over 40 countries worldwide. The primary analysis of nearly 5000 AF patients treated with dabigatran etexilate showed that the rates of stroke, major bleeding and life-threatening bleeding were low, confirming the sustained safety and effectiveness of dabigatran etexilate over two years of follow-up in clinical practice.3 These data are consistent with the long-term safety profile observed in other real-world evidence studies, as well as in randomised clinical trials.3

Both studies have helped to further confirm the safety profile of dabigatran etexilate in high risk patient populations, as well as in a real-world setting. In recognition of this, the European Medicines Agency (EMA) has recently authorised the inclusion of data from both studies within the SmPC for dabigatran etexilate in the EU.4

“Insights from the RE-DUAL PCITM and GLORIATM-AF study data have helped to further inform the positive safety profile of dabigatran etexilate for the treatment of AF patients”, said Waheed Jamal, MD, Corporate Vice President & Head of Cardiometabolic Medicine at Boehringer Ingelheim. “We are pleased to see that the value these studies bring is also acknowledged by the EMA and the medical community. This is reflected by the updates to the EU SmPC and the number of abstracts accepted for presentation at ESC Congress 2018.”

Details of the data presented at ESC Congress 2018 are as follows:

     
Abstract Title  

Details
(Venue: Messe München GmbH, Munich)

RE-DUAL PCI TM
High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCITM

SPAF-A346 (1160.186)
15:50 – 16:40, 26 Aug 2018, Moderated Poster station- Poster Area

The effect of age on the efficacy and safety of dabigatran dual therapy in atrial fibrillation after PCI: a subgroup analysis from the RE-DUAL PCITM

SPAF-A360 (1160.186)
15:50 – 16:40, 26 Aug 2018, Moderated Poster station- Poster Area

The effect of PCI complexity on the efficacy and safety of dabigatran dual therapy vs warfarin triple therapy in atrial fibrillation: a subgroup analysis from the RE-DUAL PCITM trial

SPAF-A356 (1160.186)
10:05 - 10:55, 27 Aug 2018, Moderated Poster station- Poster Area

Dual antithrombotic therapy with dabigatran vs triple therapy with warfarin after PCI in patients with atrial fibrillation and diabetes mellitus (a RE-DUAL PCITM subgroup analysis)

SPAF-A358 (1160.186)
8:30 - 12:30, 28 Aug 2018, Best Posters screen - Poster Area

GLORIA TM -AF

Two-year outcomes of dabigatran etexilate treatment in patients with co-morbid heart failure and atrial fibrillation: the GLORIATM-AF registry

SPAF-A343 (1160.129/136/171)
14:00 – 18:00, 26 Aug 2018, Posters- Poster Area

Two-year outcomes of dabigatran etexilate in patients with atrial fibrillation with and without a history of coronary artery disease: Data from GLORIATM-AF

SPAF-A354 (1160.129/136/171)
14:00 – 18:00, 26 Aug 2018, Posters- Poster Area

When are Atrial Fibrillation Patients at Risk to Discontinue Anticoagulation Treatment? Results from the GLORIATM-AF Registry

SPAF-A349 (1160.129/136/171)
14:00 – 18:00, 27 Aug 2018, Posters- Poster Area

A prospective global registry on oral antithrombotic treatment in patients with atrial fibrillation: GLORIATM-AF Phase III baseline characteristics; (1160.129/136/171)

SPAF-A347 (1160.129/136/171)
08:30 – 12:30, 27 Aug 2018, Posters- Poster Area

Geographic region, stroke risk and renal function strongly affect treatment choice for stroke prevention in patients with non-valvular AF: results from the GLORIATM-AF registry program

SPAF-A353 (1160.129/136/171)
10:05 – 10:55, 28 Aug 2018, Moderated Poster station- Poster Area

Others
Evaluation of VTE-BLEED for predicting intracranial or fatal bleedings in stable anticoagulated patients with venous thromboembolism

VTE-A72 (Study TBC)
12:35, 25 Aug 2018, Moderated Poster station- Poster Area

Safety and Effectiveness of Dabigatran Relative to Warfarin in Routine Care – Final results from a long-term monitoring program; (1160.207)

SPAF-A357 (1160.207)
12:35 - 13:25, 25 Aug 2018, Moderated Poster station - Poster Area

Trauma victims requiring dabigatran reversal with idarucizumab in RE-VERSE AD

SPAF-A356 (1160.186)
08:30 - 12:30, 27 Aug 2018, Posters- Poster Area

Making sense of real-world evidence: addressing the uncertainties surrounding anticoagulation for stroke prevention in non-valvular atrial fibrillation  

MAPOR-A42
TBC

More information on the Boehringer Ingelheim data due to be presented or published at the ESC Congress 2018 can be found here.

Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. It is directed to the international audience outside Germany. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

For references and notes to editors, please visit: https://www.boehringer-ingelheim.com/press-release/new-data-at-ESC-supports-Pradaxa-safety-profile

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Meike Bausinger
Phone: +49 6132 77 182085
Mobile: +49 151 44061760
Fax: +49 6132 77 6601
Email: press@boehringer-ingelheim.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

iMarketKorea Switches to Rimini Street Support for its SAP Application24.6.2019 22:00:00 CESTPressemelding

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that iMarketKorea, the country’s leading B2B e-commerce company, has switched from SAP to Rimini Street support for their SAP ECC system. By switching to Rimini Street, iMarketKorea was able to reduce its annual support fees by 50 percent and are now able to run their current stable ERP system for a minimum of 15 years from the time they moved to Rimini Street, without being forced to upgrade by SAP’s published 2025 end of mainstream maintenance window for ECC 6. Because of the premium level of ERP support the company now receives, iMarketKorea’s IT staff have been relieved of the day to day back office system maintenance, which is now entirely handled by Rimini Street, and are able to focus on and support more strategic projects within their company. This press release

IFF and ISIPCA Celebrate First Master of Scent Design Graduating Class24.6.2019 20:15:00 CESTPressemelding

Regulatory News: IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), a leading innovator of taste, scent, and nutrition & ingredients, and ISIPCA, a prestigious higher education institution in the field of perfume, cosmetics, and flavoring, today celebrate the first Master of Scent Design and Creation graduating class of their collaborative program, established in 2016. “This is an historic day with many reasons to celebrate,” said Nicolas Mirzayantz, Scent Division CEO, IFF. “This is the first Masters of Scent Design & Creation graduating class from the first collaboration of its kind in the industry. We are thrilled at the sheer quality and passion of the well-trained and talented class, who are poised and ready to contribute to the world of fragrance. And we are happy to see such a diverse and inclusive group, reflecting the consumers for whom they will create.” The three-year program, based in Versailles, France, offers students a strong foundation in the art of perfumery, including an

3,900-Acre Wyoming “Holy Cow Ranch” Neighboring Bighorn National Forest to Auction via Concierge Auctions24.6.2019 19:58:00 CESTPressemelding

A 3,900-acre property located halfway between Yellowstone Park and Mount Rushmore in Sheridan, Wyoming – affectionately known as Holy Cow Ranch – will auction next month via leading global firm Concierge Auctions. The property features five structures including a guest lodge and owner’s residence, a pool with pool house, tennis courts, and miles of Bighorn National Forest frontage. Previously listed for $23.5 million, 43 Rapid Creek Road will auction Without Reserve in cooperation with Bruce Garber, Joe Steger, and Roger St Clair of Century 21 BHJ Realty, Inc. Bidding, which will be held via Concierge Auctions’ online marketplace, will open July 23rd and close July 26th. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190624005652/en/ Holy Cow Ranch – Sheridan, WY (Photo: Business Wire) “The auction of Holy Cow Ranch presents the opportunity to own a truly impressive range of some of North America’s most beautiful landscapes,

 Avioq Announces CE Mark and European Launch of VioOne HIV Profile Supplemental Assay24.6.2019 15:11:00 CESTPressemelding

Avioq, Inc. has received CE Marking (Conformité Européenne) and has begun marketing their VioOne™ HIV Profile™ Supplemental Assay in the European Union and other CE Mark countries. The product has also been submitted for FDA approval. “We are pleased to provide the CE Mark HIV Profile™ assay to countries outside the U.S.,” said Chamroen Chetty, CEO of Avioq. Dr. Chetty continues, “We are also looking for distribution partners to expand the global availability.” The HIV Profile™ is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of HIV-1 (Group M & Group O) and HIV-2 in human serum or plasma that were repeatedly reactive in diagnostic screening procedures. Results can also be used to distinguish recent from longstanding HIV-1 infection for HIV-1 incidence estimation. About Confirmatory Testing In 2014, the CDC released a new algorithm for HIV testing. The second step of the algorithm includes a

Global Launch of S BLOCK, Kicked Off in Singapore on June 22nd24.6.2019 12:29:00 CESTPressemelding

The globally renowned 2019 WBF Singapore Technology Conference was held in Marina Bay Sands Hotel on June 22nd, 2019. S BLOCK, the conference co-host, unveiled itself and announce its mission to “Unleash your digital assets” for the first time. The conference brought together numerous industry elites and blockchain enthusiasts from all around the world, including more than 500 industry veterans from over 30 countries, such as Switzerland, Germany, France, Russia, Japan, Korea, Brazil, Australia, Argentina and Canada. Insiders shared profound global industry insights. This conference draws great attention from across the global blockchain industry. S BLOCK Kicked Off in Singapore In the morning of June 22nd, Ivan - President of S BLOCK Global Foundation, was invited to deliver a keynote speech, “Next Generation Digital Currency Wallet”. At this conference, S BLOCK was officially launched in more than 30 countries around the world, and opened up the way to a global future without borders

SpeeDx announce a collaborative agreement with GSK to supply tests and technology24.6.2019 12:00:00 CESTPressemelding

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed a collaborative agreement with GSK, to provide a combination of existing tests and custom test development to support certain GSK antibiotic clinical trials and new product development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190624005302/en/ “SpeeDx has a demonstrated commitment to improve patient care, and our tests currently used in clinical practice are supporting Resistance Guided Therapy, positively impacting cure rates and helping to minimise the spread of antimicrobial resistant infections.” Colin Denver, SpeeDx CEO. (Photo: Business Wire) “We welcome this extension of the utility and application of our tests and technology,” said Colin Denver, SpeeDx CEO. “SpeeDx has a demonstrated commitment to improve patient care, and our tests currently used in clinical practice are supporting Resistance Guided Therapy, positively impac